Formulation: A solid
Formal Name: 2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
Purity: ≥98%
Formula Markup: C30H50O5
Formula Weight: 490,7
Shelf life (days): 1460
CAS Number: 104121-92-8
Notes: Eldecalcitol is a derivative of the vitamin D3 receptor agonist and vitamin D3 active metabolite calcitriol (Item No. 71820).{66543,66544} It induces calcium release in an in vitro bone mobilization assay using isolated mouse calvaria when used at a concentration of 10 nM.{66543} Eldecalcitol (50 nM) reduces LPS-induced pyroptosis and increases in hydrogen peroxide and protein levels of the NOD-like receptor protein 3 (NLRP3) inflammasome, caspase-1, and IL-1β in primary human gingival fibroblasts.{66545} Eldecalcitol (0.4 nM) induces apoptosis and cell cycle arrest at the G0/G1 phase in, and inhibits migration of, SCC-15 and CAL 27 squamous cell carcinoma cells and decreases tumor volume in an SCC-15 mouse xenograft model when administered at a dose of 0.5 µg/kg twice per week.{66546} Eldecalcitol (0.3 µg/kg) decreases serum parathyroid hormone (PTH) levels and increases serum calcium levels, bone mineral density, and bone strength in a cynomolgus monkey model of osteoporosis induced by ovariectomy.{66544} Formulations containing eldecalcitol have been used in the treatment of osteoporosis.
English
Deutsch
